.svg){kind=small}
Bridging the gap in your Phase I clinical studies.
Japan’s pharmaceutical market is the second largest in the world. Japan relies on the import of pharmaceutical goods to meet the needs of the country’s population. To capitalise upon these opportunities, drug developers must comply with the strict Pharmaceuticals and Medical Devices Agency (PMDA) regulations.
Richmond Pharmacology’s expertise can help you bridge the gap in your next Phase I clinical study.
Learn about the bridging studies conducted at Richmond Pharmacology
A single centre study for Chiesi Pharmaceuticals. 16 Japanese and 16 Caucasian volunteers participated in cross over, bridging study for Chronic obstructive pulmonary disease. Read about our approach and the controls we introduced to reduce variability. Learn more here.
A cognitive function profile of a second generation antihistamine. The effect of rupatadine on cognitive functioning was evaluated by means of computerized cognitive tests: rapid visual information processing (RVP), reaction time (RT), spatial working memory (SWM) and visual analogue scales (VAS) with 27 Japanese volunteers. Learn more here.
Fast track your global marketing approvals
Our expertise can help you accelerate your drug development timelines globally
Why choose Richmond Pharmacology for your Bridging Study
Expertise in PMDA criteria
We have conducted more than 100 ethnic bridging studies enabling us to build a trusted relationship with the PMDA.
Read more +13,000 active 1st generation Japanese subjects
.svg)
Our recruitment database is the largest in Europe with more than 13,000 active 1st generation Japanese subjects.
Read more +Short- and long-term residency periods
.svg)
We can accommodate studies with short-term and long-term residency periods.
Read more +Hear from our sponsors
.svg){kind=small}
-min.jpg)
.jpg)
Latest news
Celebrating Clinical Trials Day 2023
Futureproofing early phase clinical research for the next generation of investigators.
Events
HFA Annual Meeting 2023
